FocusPolicy

Medication development in opioid addiction: Meaningful clinical end points

See allHide authors and affiliations

Science Translational Medicine  28 Mar 2018:
Vol. 10, Issue 434, eaan2595
DOI: 10.1126/scitranslmed.aan2595

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

The FDA’s “abstinence” outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.

View Full Text